Evaluación de la calidad del huevo marrón comercial del cantón La Troncal, Ecuador

The quality of commercial brown egg from the county La Troncal, Ecuador, was evaluated. A total of 1,200 eggs were studied (parish La Troncal, 400 eggs; parish Manuel J. Calle, 400 eggs and parish Pancho Negro, 400 eggs). The external physical analysis was performed, which includes egg weight, thickness and shell weight, and the internal physical analysis, which includes diameter, and height of white and yolk. Eggs were classified according to color, weight and shape. Each parish was considered a treatment and means of variables of the external and internal physical analyses were separated using the Tukey test (p≤0.05). Colors 90, 100 and 110 were the most frequent. According to egg weight, the most frequent categories were extralarge (38%), large (30%) and giant (19%). According to shape, the highest frequency was of ovoid and round eggs (92%), being more frequent, between these two categories, the ovoid eggs. Birds from Manuel J. Calle parish produced (p≤0.05) larger eggs, with greater diameter and white height, higher yolk height, greater weight and shell thickness, a darker brown color and mostly ovoid eggs, while the other parishes produced slightly lower values. In conclusion, the parishes of La Troncal, Ecuador, produce large eggs, with good diameter and white height, and a really brown color, that is, they produce very good quality eggs.Se evaluó la calidad del huevo marrón comercial del cantón La Troncal, Ecuador. Se estudiaron un total de 1200 huevos (parroquia La Troncal, 400 huevos; parroquia Manuel J. Calle, 400 huevos y parroquia Pancho Negro, 400 huevos). Se realizó el análisis físico externo que incluye peso de huevo, espesor y peso de cáscara, y el análisis físico interno, que incluye diámetro, y altura de clara y de yema. Se clasificaron los huevos según color, peso y forma. Cada parroquia se consideró un tratamiento y las medias de las variables del análisis físico externo y del interno, fueron separadas utilizando la prueba de Tukey (p≤0.05). Los colores 90, 100 y 110, fueron los más frecuentes. Según el peso del huevo, las categorías más frecuentes fueron extragrande (38%), grande (30%) y gigante (19%). Según la forma, la mayor frecuencia fue de huevos ovoides y redondos (92%), siendo más frecuentes, entre estas dos categorías, los huevos ovoides. Las aves de la parroquia Manuel J. Calle produjeron (p≤0.05) huevos más grandes, con mayor diámetro y altura de clara, con mayor altura de yema, con mayor peso y espesor de cáscara, color marrón más obscuro y principalmente huevos ovoides, mientras que las demás parroquias produjeron valores levemente inferiores. En conclusión, las parroquias de La Troncal, Ecuador, producen huevos grandes, con buen diámetro y altura de clara, y color francamente marrón, es decir producen huevos de muy buena calidad

Rotavirus gastroenteritis in Latin America: a hospital-based study in children under 3 years of age

GlaxoSmithKline (GSK) Biologicals was the funding source and was involved in all stages of the study conduct and analysis. GSK Biologicals also funded all costs associated with the development and the publishing of the present manuscript.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Instituto Nacional de Pediatría. México D.F., Mexico.Hospital del Niño. Panama City, Panama.Universidad de Valparaíso. Escuela de Medicina. Valparaíso, Chile.Instituto Costarricense de Investigaciones Clínicas. Urbanización de Los Arboles La Uruca. San José, Costa Rica.Instituto Mexicano del Seguro Social. CMN-SXX. Pediatrics Hospital. Medical Research Unit on Infectious Diseases. Mexico City, Mexico.GlaxoSmithKline Biologicals México. México D.F., México.Hospital Dr. Humberto Notti. Villa Nueva de Guaymallén, Mendoza, Argentina.Hospital Maternidad Nuestra Sra de la Altagracia. Santo Domingo, D.N., Dominican Republic.GlaxoSmithKline Biologicals Argentina. Victoria, Buenos Aires, Argentina.Organización para el Desarrollo y la Investigación Salud en Honduras. Colonia Humuya, Sendero Pastizal, Tegucigalpa, Honduras.Ciudad Hospitalaria Dr. Enrique Tejera. Hospital de Niños Dr. Jorge Lizarraga. Carabobo, Valencia, Venezuela.Fundación para el Avance de la Investigación Clínica y Translacional. Consultores Médicos América. Vía España, Carrasquilla, Panama.GlaxoSmithKline Biologicals Costa Rica. San Jose, Costa Rica.GlaxoSmithKline Biologicals Belgium. Rixensart, Belgium.Rotavirus is the leading cause of severe diarrheal disease and dehydration in infants in both developed and developing countries. Vaccines have recently been developed, but detailed epidemiological information, which is needed for decisions about how and where to introduce vaccination, was lacking for many Latin American countries. The primary objective of this study was to measure the incidence and disease burden of rotavirus in young children presenting to Latin American hospitals with gastroenteritis. In addition it allowed to setting up the methodology to further conduct a large phase III trial with a rotavirus vaccine in the region. This was a prospective, multi-center surveillance study of gastroenteritis in children <3 years old presenting to hospitals in 11 Latin American countries. Questionnaires and stool samples were collected from 6521 of 8031 enrolled cases (73% inpatients). Among these, 3122 (49%) were rotavirus positive. Of the rotavirus-positive cases, 12% were <6 months, 48% <1 year and 87% <2 years old; 23% received antibiotics before diagnosis. Median hospital stay was 2 days, 78% received intravenous rehydration. Overall strain distribution was G1 (59%), G2 (1%), G3 (12%), G4 (20%), G9 (6%), G12 (1%), untypable (7%) with large local variations. The direct economic impact on families was considerable: 48% of caregivers lost time from paid work and 69% of families were financially affected by their child's illness. This study confirms the high disease burden of rotavirus gastroenteritis among children in Latin America, which might be reduced by the use of effective vaccines

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

Background Peak incidence of rotavirus gastroenteritis is seen in infants between 6 and 24 months of age. We therefore aimed to assess the 2-year efficacy and safety of an oral live attenuated human rotavirus vaccine for prevention of severe gastroenteritis in infants. Methods 15183 healthy infants aged 6-13 weeks from ten Latin American countries randomly assigned in a 1 to 1 ratio to receive two oral doses of RIX4414 or placebo at about 2 and 4 months of age in a double-blind, placebo-controlled phase III study were followed up until about 2 years of age. Primary endpoint was vaccine efficacy from 2 weeks after dose two until 1 year of age. Treatment allocation was concealed from investigators and parents of participating infants. Efficacy follow-up for gastroenteritis episodes was undertaken from 2 weeks after dose two until about 2 years of age. Analysis was according to protocol. This study is registered with ClinicalTrials.gov, number NCT00140673 (eTrack444563-023). Findings 897 infants were excluded from the according-to-protocol analysis. Fewer cases (p<0.0001) of severe rotavirus gastroenteritis were recorded for the combined 2-year period in the RIX4414 group (32 [0.4%] of 7205; 95% CI 0 . 3-0.6) than in the placebo group (161 [2.3%] of 7081; 1 . 9-2.6), resulting in a vaccine efficacy of 80.5% (71.3-87. 1) to 82.1% (64.6-91.9) against wild-type G1, 77.5% (64.7-86.2) against pooled non-G1 strains, and 80.5% (67.9-88 . 8) against pooled non-G1 P[81 strains. Vaccine efficacy for hospital admission for rotavirus gastroenteritis was 83. 0% (73.1-89.7) and for admission for diarrhoea of any cause was 39.3% (29.1-48 . 1). No cases of intussusception were reported during the second year of follow-up. Interpretation Two doses of RIX4414 were effective against severe rotavirus gastroenteritis during the first 2 years of life in a Latin American setting. Inclusion of RIX4414 in routine paediatric immunisations should reduce the burden of rotavirus gastroenteritis worldwide

Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres

© 2018 The Authors Background: A quadrivalent split-virion inactivated influenza vaccine (VaxigripTetra™ Sanofi Pasteur; IIV4) containing two A strains (H1N1 and H3N2) and B strains from both lineages (Victoria and Yamagata) was approved in Europe in 2016 for individuals aged ≥ 3 years. This study examined the efficacy and safety of IIV4 in children aged 6–35 months. Methods: This was a phase III randomised controlled trial conducted in Latin America, Asia, Africa, and Europe during the Northern Hemisphere 2014/2015 and 2015/2016 and Southern Hemisphere 2014 and 2015 influenza seasons. Healthy children aged 6–35 months not previously vaccinated against influenza were randomised to receive two full doses 28 days apart of IIV4, placebo, the licensed trivalent split-virion inactivated vaccine (IIV3), an investigational IIV3 containing a B strain from the alternate lineage. The primary objective was to demonstrate efficacy against influenza illness caused by any strain or vaccine-similar strains. Results: The study enrolled 5806 participants. Efficacy, assessed in 4980 participants completing the study according to protocol, was demonstrated for IIV4. Vaccine efficacy was 50.98% (97% CI, 37.36–61.86%) against influenza caused by any A or B type and 68.40% (97% CI, 47.07–81.92%) against influenza caused by vaccine-like strains. Safety profiles were similar for IIV4, placebo, and the IIV3s, although injection-site reactions were slightly more frequent for IIV4 than placebo. Conclusions: IIV4 was safe and effective for protecting children aged 6–35 months against influenza illness caused by vaccine-similar or any circulating strains. Clinical trial registration: EudraCT no. 2013-001231-51

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

BACKGROUND: In a parallel-group, international, phase 3 study (ClinicalTrials.govNCT04762680), we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein booster vaccines with AS03-adjuvant (CoV2 preS dTM-AS03). METHODS: Adults, previously primed with mRNA (BNT162b2, mRNA-1273), adenovirus-vectored (Ad26.CoV2.S, ChAdOx1nCoV-19) or protein (CoV2 preS dTM-AS03 [monovalent D614; MV(D614)]) vaccines were enrolled between 29 July 2021 and 22 February 2022. Participants were stratified by age (18-55 and ≥ 56 years) and received one of the following CoV2 preS dTM-AS03 booster formulations: MV(D614) (n = 1285), MV(B.1.351) (n = 707) or bivalent D614 + B.1.351 (BiV; n = 625). Unvaccinated adults who tested negative on a SARS-CoV-2 rapid diagnostic test (control group, n = 479) received two primary doses, 21 days apart, of MV(D614). Anti-D614G and anti-B.1.351 antibodies were evaluated using validated pseudovirus (lentivirus) neutralization (PsVN) assay 14 days post-booster (day [D]15) in 18-55-year-old BNT162b2-primed participants and compared with those pre-booster (D1) and on D36 in 18-55-year-old controls (primary immunogenicity endpoints). PsVN titers to Omicron BA.1, BA.2 and BA.4/5 subvariants were also evaluated. Safety was evaluated over a 12-month follow-up period. Planned interim analyses are presented up to 14 days post-last vaccination for immunogenicity and over a median duration of 5 months for safety. FINDINGS: All three boosters elicited robust anti-D614G or -B.1.351 PsVN responses for mRNA, adenovirus-vectored and protein vaccine-primed groups. Among BNT162b2-primed adults (18-55 years), geometric means of the individual post-booster versus pre-booster titer ratio (95% confidence interval [CI]) were: for MV (D614), 23.37 (18.58-29.38) (anti-D614G); for MV(B.1.351), 35.41 (26.71-46.95) (anti-B.1.351); and for BiV, 14.39 (11.39-18.28) (anti-D614G) and 34.18 (25.84-45.22 (anti-B.1.351). GMT ratios (98.3% CI) versus post-primary vaccination GMTs in controls, were: for MV(D614) booster, 2.16 (1.69; 2.75) [anti-D614G]; for MV(B.1.351), 1.96 (1.54; 2.50) [anti-B.1.351]; and for BiV, 2.34 (1.84; 2.96) [anti-D614G] and 1.39 (1.09; 1.77) [anti-B.1.351]. All booster formulations elicited cross-neutralizing antibodies against Omicron BA.2 (across priming vaccine subgroups), Omicron BA.1 (BNT162b2-primed participants) and Omicron BA.4/5 (BNT162b2-primed participants and MV D614-primed participants). Similar patterns in antibody responses were observed for participants aged ≥56 years. Reactogenicity tended to be transient and mild-to-moderate severity in all booster groups. No safety concerns were identified. INTERPRETATION: CoV2 preS dTM-AS03 boosters demonstrated acceptable safety and elicited robust neutralizing antibodies against multiple variants, regardless of priming vaccine. FUNDING: Sanofi and Biomedical Advanced Research and Development Authority (BARDA)

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group studyResearch in context

Summary: Background: In a parallel-group, international, phase 3 study (ClinicalTrials.gov NCT04762680), we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein booster vaccines with AS03-adjuvant (CoV2 preS dTM-AS03). Methods: Adults, previously primed with mRNA (BNT162b2, mRNA-1273), adenovirus-vectored (Ad26.CoV2.S, ChAdOx1nCoV-19) or protein (CoV2 preS dTM-AS03 [monovalent D614; MV(D614)]) vaccines were enrolled between 29 July 2021 and 22 February 2022. Participants were stratified by age (18–55 and ≥ 56 years) and received one of the following CoV2 preS dTM-AS03 booster formulations: MV(D614) (n = 1285), MV(B.1.351) (n = 707) or bivalent D614 + B.1.351 (BiV; n = 625). Unvaccinated adults who tested negative on a SARS-CoV-2 rapid diagnostic test (control group, n = 479) received two primary doses, 21 days apart, of MV(D614). Anti-D614G and anti-B.1.351 antibodies were evaluated using validated pseudovirus (lentivirus) neutralization (PsVN) assay 14 days post-booster (day [D]15) in 18–55-year-old BNT162b2-primed participants and compared with those pre-booster (D1) and on D36 in 18–55-year-old controls (primary immunogenicity endpoints). PsVN titers to Omicron BA.1, BA.2 and BA.4/5 subvariants were also evaluated. Safety was evaluated over a 12-month follow-up period. Planned interim analyses are presented up to 14 days post-last vaccination for immunogenicity and over a median duration of 5 months for safety. Findings: All three boosters elicited robust anti-D614G or -B.1.351 PsVN responses for mRNA, adenovirus-vectored and protein vaccine-primed groups. Among BNT162b2-primed adults (18–55 years), geometric means of the individual post-booster versus pre-booster titer ratio (95% confidence interval [CI]) were: for MV (D614), 23.37 (18.58–29.38) (anti-D614G); for MV(B.1.351), 35.41 (26.71–46.95) (anti-B.1.351); and for BiV, 14.39 (11.39–18.28) (anti-D614G) and 34.18 (25.84–45.22 (anti-B.1.351). GMT ratios (98.3% CI) versus post-primary vaccination GMTs in controls, were: for MV(D614) booster, 2.16 (1.69; 2.75) [anti-D614G]; for MV(B.1.351), 1.96 (1.54; 2.50) [anti-B.1.351]; and for BiV, 2.34 (1.84; 2.96) [anti-D614G] and 1.39 (1.09; 1.77) [anti-B.1.351]. All booster formulations elicited cross-neutralizing antibodies against Omicron BA.2 (across priming vaccine subgroups), Omicron BA.1 (BNT162b2-primed participants) and Omicron BA.4/5 (BNT162b2-primed participants and MV D614-primed participants). Similar patterns in antibody responses were observed for participants aged ≥56 years. Reactogenicity tended to be transient and mild-to-moderate severity in all booster groups. No safety concerns were identified. Interpretation: CoV2 preS dTM-AS03 boosters demonstrated acceptable safety and elicited robust neutralizing antibodies against multiple variants, regardless of priming vaccine. Funding: Sanofi and Biomedical Advanced Research and Development Authority (BARDA)

Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres

Background: A quadrivalent split-virion inactivated influenza vaccine (VaxigripTetre (TM), Sanofi Pasteur; IIV4) containing two A strains (H1N1 and H3N2) and B strains from both lineages (Victoria and Yamagata) was approved in Europe in 2016 for individuals aged &gt;= 3 years. This study examined the efficacy and safety of IIV4 in children aged 6-35 months. Methods: This was a phase III randomised controlled trial conducted in Latin America, Asia, Africa, and Europe during the Northern Hemisphere 2014/2015 and 2015/2016 and Southern Hemisphere 2014 and 2015 influenza seasons. Healthy children aged 6-35 months not previously vaccinated against influenza were randomised to receive two full doses 28 days apart of IIV4, placebo, the licensed trivalent splitvirion inactivated vaccine (IIV3), an investigational IIV3 containing a B strain from the alternate lineage. The primary objective was to demonstrate efficacy against influenza illness caused by any strain or vaccine-similar strains. Results: The study enrolled 5806 participants. Efficacy, assessed in 4980 participants completing the study according to protocol, was demonstrated for IIV4. Vaccine efficacy was 50.98% (97% CI, 37.36-61.86%) against influenza caused by any A or B type and 68.40% (97% CI, 47.07-81.92%) against influenza caused by vaccine-like strains. Safety profiles were similar for IIV4, placebo, and the IIV3s, although injection-site reactions were slightly more frequent for IIV4 than placebo. Conclusions: IIV4 was safe and effective for protecting children aged 6-35 months against influenza illness caused by vaccine-similar or any circulating strains. (C) 2018 The Authors. Published by Elsevier Ltd

XIII Jornada de Investigación 2022

Los desafíos en las dinámicas económicas, sociales, políticas y psicológicas han puesto de relieve la importancia de involucrar en la enseñanza universitaria actividades que conecten a los estudiantes con las realidades del contexto en el que se desarrollan; simultáneamente, hoy más que nunca se hace evidente que la ciencia, la tecnología y la innovación (CTI) son cruciales para atender los retos sociales, ambientales y económicos de las sociedades actuales. En este contexto, la Jornada de Investigación de la Universidad Católica de Colombia es quizás uno de los espacios institucionales más emblemáticos en el que se visibilizan las actividades en CTI de estudiantes, jóvenes investigadores y profesores, que buscan contribuir a la solución de problemáticas relevantes del entorno. En esta oportunidad, aproximadamente 177 autores y más de 250 espectadores se dieron cita en un escenario virtual que permitió el intercambio de saberes y conocimientos en torno a muchos temas con un lenguaje común: el bienestar de la humanidad y la respuesta efectiva a los retos que tenemos como comunidad. Esta cuarta versión de las Memorias compila las ponencias presentadas en la XIII Jornada de Investigación de 2022, enmarcadas en los tres ejes temáticos de investigación que tiene la Universidad Católica de Colombia: i) Derecho, Cultura y Sociedad, ii) Desarrollo Humano y Sostenible, y iii) Gestión de la Tecnología al Servicio de la Sociedad. Desde la Dirección Central de Investigaciones nos encontramos profundamente agradecidos con todos y cada uno de los participantes, y nos sentimos aún más orgullosos por la calidad de los trabajos presentados. Sea esta la oportunidad para hacer extensiva una felicitación a los autores y a las diferentes Unidades Académicas que, con su compromiso e invaluable labor, permitieron que este evento se desarrollara con éxito.Persona, hospitalidad y construcción de comunidad desde la fraternidad. José Martí: acerca de la libertad en la condición humana. Moda, imagen y alimentación: una tríada para el bien y para el mal. Lecciones de la pandemia de covid-19: conflictos entre la protección jurídica de las patentes farmacéuticas y el interés general de la salud pública. Psicología y sexualidad: propuesta para la formación de psicólogos colombianos. Estrategias para el desarrollo de herramientas que fomentan el aprendizaje para el reconocimiento y la apropiación del patrimonio cultural. Análisis descriptivo de relatos honestos y deshonestos por medio del sistema de evaluación global. El uso de la herramienta LIWC para el estudio de relatos altruistas y prosociales. ¿De qué manera influyen las redes sociales como medio de información en campañas políticas?. Sistema de Seguridad Social en Colombia: una crisis deficitaria que se refuerza con el tiempo. Turismo sexual en menores de edad: problemática endémica en el territorio colombiano. Transgresión de los derechos humanos en relación con los asesinatos de líderes sociales en el Estado colombiano. El nuevo escenario para la procedencia de la eutanasia en Colombia: una mirada desde los derechos humanos. Protección de los derechos de la infancia frente a los grupos al margen de la ley. El derecho a un nivel de vida adecuado: un enfoque hacia el desplazamiento forzado de los pueblos indígenas. Tráfico de órganos humanos: delito transnacional que vulnera los derechos humanos y su regulación en el marco jurídico colombiano. Transgresión de los derechos a la vida y la libertad en el sistema penitenciario como consecuencia de la violencia social. Acceso a la justicia colombiana en tiempos de SARS-CoV-2. Prioridades para la administración de justicia penal en Colombia: ¿balanceando espectáculo e indicadores de eficacia? Desarrollo de competencias para la investigación en neuropsicología: experiencia del semillero experimental. La dificultad al ingreso de los centros geriátricos. Principio de realidad sobre la formalidad constitucional en contrato verbal laboral en un satélite del Consultorio Jurídico de la Universidad Católica de Colombia. La pena de muerte en colisión con los derechos fundamentales. Maternidad subrogada: objetificación y vulneración de los derechos de la mujer. Una dieta inconsciente hacia el vegetarianismo. Sistema de evaluación del bienestar gerontológico para un diseño arquitectónico sostenible. Caso de estudio: hogar de paso San Francisco de Asís, Villavicencio, Meta. Revisión sistemática interacción líder-colaborador: futuras investigaciones. Análisis conceptual del talento académico desde los modelos teóricos que lo sustentan. Identificación de potenciales factores de riesgo suicida: una mirada contextual. La regulación emocional en tiempos de coronavirus. GEES: Guía de Evaluación de Edificaciones Sostenibles, vivienda de interés social, clima cálido húmedo. Estructura proyectual y sostenible para el diseño y desarrollo de un modelo de vivienda de madera en San Andrés y Providencia, Colombia. Innovación social para la gestión territorial. Construcción de material didáctico para el entrenamiento en habilidades de regulación emocional e interpersonales dirigidas a poblaciones expuestas a situaciones de violencia política. Alternativas sostenibles de modelos de desarrollo industrial. La ruralidad dentro de los procesos del desarrollo local en Usme. Se ha dejado de dibujar arquitectura con las manos. Calidad de vida, bienestar y felicidad en el trabajo: una revisión sistemática de la literatura científica, 2011-2021. Autonomía, autorregulación y educación moral: reflexiones desde la psicología del desarrollo moral. Características de los niños, niñas y adolescentes expuestos a contextos de conflicto armado en Colombia. Revisión bibliométrica de artículos sobre la crianza en niños, niñas y adolescentes colombianos. Narrativas sociales en el proceso de cualificación de lo público La habitación exterior como extensión de la vivienda. Utilización de nanopartículas magnéticas Fe3O4 y ozono para la degradación/eliminación de azul de metileno en agua residual textil. Estudio paramétrico de un modelo numérico Fem de un ensayo CBR. ¿Cómo construir identidad de manera incluyente a partir del reconocimiento de patrimonio cultural construido?. Veracidad de los resultados del ensayo de penetración dinámica de CONO(PDC). Análisis de texto a partir del procesamiento de lenguaje natural para identificar sintomatología depresiva en redes sociales. Análisis de texto para la detección de depresión en comentarios de usuarios de la red social Instagram. Diseño y desarrollo de un videojuego para evaluar la interacción de las redes atencionales en la sintomatología depresiva. Herramienta tecnológica para el apoyo en la detección de sintomatología ansiosa en jóvenes. Optimización del despliegue de aplicaciones web a partir de computación en nube sin servidor. Prototipo alfa de un videojuego serio para el apoyo en la detección de sintomatología depresiva en adultos jóvenes. La importancia de la visualización de datos en la era del Big Data y sus herramientas. Prototipo de sensor para el registro electroencefalográfico. Prototipo de un algoritmo basado en inteligencia artificial para el apoyo a especialistas en el diagnóstico del Alzheimer. Evaluación posocupacional del confort térmico en la vivienda social: análisis de una revisión sistemática prisma desde el diseño resiliente. Inteligencia artificial, problema u oportunidad para el Derecho. Impacto en el empleo en relación con las TIC y la inteligencia artificial. Neuroprivacidad. El test de asociación implícita, un paradigma que permite abordar nuestras actitudes inconscientes. ¿Cuál es el límite del uso de las tecnologías frente al derecho de información y de la libre expresión?. Tendencias de fijación de precios basados en el valor: un análisis desde la minería de datos. Recorrido virtual de la Universidad Católica de Colombia Sede Claustro para la inducción de estudiantes y docentes. Introducción a la bioarquitectura del paisaje, cartilla Paisaje, ambiente y tecnología. Descripción plan piloto (Choachí). Caracterización de las habilidades específicas para el reconocimiento del patrimonio cultural – Borde urbano sur oriental de Bogotá. Videojuego para estimular la memoria episódica en pacientes con deterioro cognitivo leve: validación de contenido. CONCLUSIONESTercera edició